Arkolith/Insider Trading/TEVA/Form 4

Kalif Eliyahu Sharon

EVP, Chief Financial OfficerTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) · full profile →Form 4 · filed Mar 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)23K——306K
Mar 4, 2026Option exercise(M)34K——282K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Grant(A)53K—$053K
Mar 4, 2026Option exercise(M)23K—$047K
Mar 4, 2026Option exercise(M)34K—$00

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-096513) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML